 |
How Much are Marketing & Sales Capabilities Really Worth? | | | | | | | Summary | | | | New Accenture research finds that, unequivocally, successful marketing and sales capabilities differentiate Europe’s best performing pharmaceutical companies. Next: Key Findings |
| | | Key Findings | - Approximately 70 percent of the difference in return on sales between companies can be explained in this way, making marketing and sales highly potent indicators of financial performance.
- In an average European country operation with a turnover of $300-500 million, this difference could represent an additional marketing contribution of $40-70 million.
Next: Analysis |
| | | Analysis | This pioneering research in European pharmaceuticals explores these capabilities in a systematic way, supporting and complementing our North American study and pointing out some subtle differences between these markets. With marketing and sales typically accounting for up to 45 percent of the pharmaceutical cost base, regardless of performance, Accenture helps clients understand which marketing and sales capabilities differentiate the top performers from the rest. View US study. Return to Summary |
|
|
|
|
|